Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N, Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A, Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R, Vallathol DH, Dsouza H, Shrirangwar S, Turkar S, Abraham G, Thanky AH, Patel U, Pandey MK, Prabhash K. Patil VM, et al. Among authors: vallathol dh. Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31. Cancer. 2019. PMID: 31150120 Free article. Clinical Trial.
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Patil V, Noronha V, Dhumal SB, Joshi A, Menon N, Bhattacharjee A, Kulkarni S, Ankathi SK, Mahajan A, Sable N, Nawale K, Bhelekar A, Mukadam S, Chandrasekharan A, Das S, Vallathol D, D'Souza H, Kumar A, Agrawal A, Khaddar S, Rathnasamy N, Shenoy R, Kashyap L, Rai RK, Abraham G, Saha S, Majumdar S, Karuvandan N, Simha V, Babu V, Elamarthi P, Rajpurohit A, Kumar KAP, Srikanth A, Ravind R, Banavali S, Prabhash K. Patil V, et al. Lancet Glob Health. 2020 Sep;8(9):e1213-e1222. doi: 10.1016/S2214-109X(20)30275-8. Lancet Glob Health. 2020. PMID: 32827483 Free article. Clinical Trial.
RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.
Patil V, Noronha V, Joshi A, Menon N, Mathrudev V, Bhattacharjee A, Chandrasekharan A, Vallathol D, Dsouza H, Srinivas S, Mandal T, Chaturvedi P, Chaukar D, Pai P, Nair S, Thiagrajan S, Laskar S, Nawale K, Babanrao Dhumal S, Tambe R, Banavali S, Prabhash K. Patil V, et al. Oral Oncol. 2022 May;128:105816. doi: 10.1016/j.oraloncology.2022.105816. Epub 2022 Mar 31. Oral Oncol. 2022. PMID: 35367787 Clinical Trial.
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Noronha V, et al. Among authors: vallathol dh. J Clin Oncol. 2018 Apr 10;36(11):1064-1072. doi: 10.1200/JCO.2017.74.9457. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220295 Clinical Trial.
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.
Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Patil V, et al. Among authors: vallathol dh. EClinicalMedicine. 2019 Apr 9;9:19-25. doi: 10.1016/j.eclinm.2019.03.011. eCollection 2019 Mar. EClinicalMedicine. 2019. PMID: 31143878 Free PMC article.
Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma.
Kumar G, DSouza H, Menon N, Srinivas S, Vallathol DH, Boppana M, Rajpurohit A, Mahajan A, Janu A, Chatterjee A, Krishnatry R, Gupta T, Jalali R, Patil VM. Kumar G, et al. Among authors: vallathol dh. Ecancermedicalscience. 2021 Jan 13;15:1166. doi: 10.3332/ecancer.2021.1166. eCollection 2021. Ecancermedicalscience. 2021. PMID: 33680080 Free PMC article.
Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center.
Patil VM, Chandrasekharan A, Vallathol DH, Malhotra M, Abhinav R, Agarwal P, Rajpurohit A, Tonse R, Bhattacharjee A, Jalali R. Patil VM, et al. Among authors: vallathol dh. Neurooncol Pract. 2019 Dec;6(6):479-483. doi: 10.1093/nop/npz009. Epub 2019 Apr 19. Neurooncol Pract. 2019. PMID: 31832218 Free PMC article.
Thromboembolic events in brain tumour patients on bevacizumab.
Singh GK, Menon N, Jadhav MM, Walavalkar R, DSouza H, Roy S, Das S, Srinivas S, Vallathol DH, Patil VM. Singh GK, et al. Among authors: vallathol dh. Acta Oncol. 2020 Dec;59(12):1543-1546. doi: 10.1080/0284186X.2020.1815834. Epub 2020 Sep 8. Acta Oncol. 2020. PMID: 32897111 No abstract available.
13 results